Yili Chuanning Biotechnology Co.,Ltd.

SZSE:301301 Stock Report

Market Cap: CN¥27.5b

Yili Chuanning BiotechnologyLtd Future Growth

Future criteria checks 1/6

Yili Chuanning BiotechnologyLtd is forecast to grow earnings and revenue by 14.9% and 10% per annum respectively. EPS is expected to grow by 15.6% per annum. Return on equity is forecast to be 17.7% in 3 years.

Key information

14.9%

Earnings growth rate

15.6%

EPS growth rate

Biotechs earnings growth43.6%
Revenue growth rate10.0%
Future return on equity17.7%
Analyst coverage

Low

Last updated22 Oct 2024

Recent future growth updates

Recent updates

These 4 Measures Indicate That Yili Chuanning BiotechnologyLtd (SZSE:301301) Is Using Debt Safely

Oct 11
These 4 Measures Indicate That Yili Chuanning BiotechnologyLtd (SZSE:301301) Is Using Debt Safely

If EPS Growth Is Important To You, Yili Chuanning BiotechnologyLtd (SZSE:301301) Presents An Opportunity

Jul 23
If EPS Growth Is Important To You, Yili Chuanning BiotechnologyLtd (SZSE:301301) Presents An Opportunity

We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease

May 31
We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease

Yili Chuanning BiotechnologyLtd (SZSE:301301) Could Easily Take On More Debt

Feb 26
Yili Chuanning BiotechnologyLtd (SZSE:301301) Could Easily Take On More Debt

Earnings and Revenue Growth Forecasts

SZSE:301301 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20267,1191,910N/A2,2813
12/31/20256,5431,700N/A2,0373
12/31/20245,8761,437N/A1,4783
9/30/20245,6981,3768441,065N/A
6/30/20245,6021,3167421,029N/A
3/31/20245,0771,1181,2141,608N/A
12/31/20234,8239419471,292N/A
9/30/20234,4627191,6931,898N/A
6/30/20234,2545651,5441,668N/A
3/31/20234,093486601643N/A
1/1/20233,821412644692N/A
9/30/20223,634272127223N/A
3/31/20223,345154922977N/A
1/1/20223,232111751803N/A
12/31/20203,649229561650N/A
12/31/20193,14391-212-147N/A
12/31/20183,349390280310N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 301301's forecast earnings growth (14.9% per year) is above the savings rate (2.8%).

Earnings vs Market: 301301's earnings (14.9% per year) are forecast to grow slower than the CN market (25.5% per year).

High Growth Earnings: 301301's earnings are forecast to grow, but not significantly.

Revenue vs Market: 301301's revenue (10% per year) is forecast to grow slower than the CN market (13.7% per year).

High Growth Revenue: 301301's revenue (10% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 301301's Return on Equity is forecast to be low in 3 years time (17.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:56
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Yili Chuanning Biotechnology Co.,Ltd. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Chao LiCitic Securities Co., Ltd.
Ban WangMinsheng Securities Co.